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Abstract
Background: We examined incidence and survival in relation to age, gender, socioeconomic deprivation, rurality and
trends over time. We also examined the association between volume of patients treated by hospitals and survival.
Methods: Incident cases (2001–12) were identified using comprehensive National Health Service admissions data for
England, with follow-up to March 2013. Socioeconomic deprivation was based on census area of residence. Volume
was assessed in a three-year subset of the data with consistent hospital provider codes.
Results: There were 2921 adults aged 18 or more years diagnosed with acute lymphoblastic leukaemia (ALL) in the 12-
year time span, giving a crude annual incidence of 0.61/100,000 population. Five-year survival was 32% (1870 deaths).
Compared with patients living in least deprived areas, survival was worse for patients living in intermediate and most
deprived areas, with mortality hazard ratios 21% (95% CI 8–35%) and 16% (95% CI 3–30%) higher respectively.
Hospitals treating low volumes of adults with ALL were associated with poorer survival. The adjusted mortality hazard
ratio in this subset of 465 patients was 33% (95% CI 3–73%) higher in low volume hospitals.
There was no evidence of association between socioeconomic deprivation and incidence. Rurality did not appear to
be associated with incidence or survival. Incidence was higher in men but there was no evidence of a gender
difference in survival. Survival improved over time.
Conclusion: The associations between socioeconomic deprivation and survival and between volume and outcome for
adults with ALL, if confirmed, are likely to have significant implications for the organisation of services for adults with ALL.
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Background
Acute lymphoblastic leukaemia (ALL) is a haemato-
logical malignancy arising from lymphoblasts. Whilst
it is a relatively common malignancy in children
with a higher incidence in boys, the incidence is rare
in adults. The prognosis is good in childhood ALL
but is poor in the adult form of the disease [1]. The
epidemiology of childhood ALL has been well docu-
mented but much less has been done on the epi-
demiology in adults.
Socioeconomic inequalities in health are a major cause
of concern and socioeconomic deprivation is associated
with the incidence and prognosis of many conditions
[2]. With regard to the incidence of ALL in childhood, a
review of early studies found that higher incidence ap-
peared to be associated with higher socioeconomic sta-
tus [3]. However, another review which included several
subsequent studies found conflicting evidence [4]. Little
has been done on the incidence of ALL in adults in rela-
tion to socioeconomic deprivation and a study of young
adults found no evidence of association [5].
The association between socioeconomic deprivation
and survival has been examined in a number of studies
on childhood ALL, with poorer survival associated with
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deprivation in several studies but not others [5–10]. Lit-
tle research, however, has been carried out on the associ-
ation between socioeconomic deprivation and survival in
adults with ALL, with no significant association found in
young adults [5].
The association between the volume of patients treated
at a hospital and outcome has significant implications for
the organisation and centralisation of services and has
been investigated in relation to an increasing range of con-
ditions, including medical and surgical care for cancer pa-
tients [11]. With regard to ALL, centres treating a high
volume of childhood ALL cases were found to have better
outcomes in some studies but not others [12–14]. How-
ever, the association between volume and outcome has
not been investigated in relation to ALL in adults.
Trends over time and geographical variation are other
aspects relevant to the epidemiology of ALL in adults. In
one region in the UK, there appeared to be no improve-
ment in survival of young adults diagnosed between 1990
and 2002 [5]. However, studies in other countries which
included more recent years have reported improvements
in survival over time [15, 16]. International and within
country geographical variation in ALL incidence and sur-
vival has been examined, although mainly in children or
with all ages combined [1, 5, 10]. Little, however, has been
done on the differences in incidence and survival between
urban and rural areas in relation to adults with ALL.
We examined the incidence and survival of adults with
ALL in relation to age, gender, socioeconomic
deprivation, rurality and trends over time. We also ex-
amined the association between volume of patients
treated by hospital providers and survival.
Methods
Study design, area and time span
We used a population (ecological) study design to inves-
tigate incidence and a cohort study design to examine
survival amongst all adult patients (aged 18 years or
more at diagnosis) in England diagnosed from 2001 to
2012. Follow-up was to 31st March 2013. The study was
approved by the University of Sheffield’s Research Ethics
Committee. Participant consent was not necessary as
this study involved the use of de-identified Hospital Epi-
sode Statistics (HES) supplied by NHS Digital. NHS
Digital is an executive non-departmental public body ac-
countable to Parliament and its statutory role is set out
in the Health and Social Care Act 2012.
Data on cases
We used pseudoanonymised HES data with linked mortal-
ity data to identify cases with ALL. HES is a data ware-
house containing details of all admissions to National
Health Service (NHS) hospitals in England [17]. Admis-
sions are recorded as “episodes” where an episode is a
period of care under a single consultant during an admis-
sion. An admission may comprise more than one episode
if a patient is transferred from the care of one consultant
to another during the admission, though in practice most
admissions comprise a single episode. The admission epi-
sode record includes several diagnosis and procedure code
fields. We used the first seven diagnosis fields and the first
12 procedure code fields in order to use a set that was
consistent throughout the study time span (there were
more fields in later years). HES years follow the UK finan-
cial calendar and run from 1st April to 31st March the fol-
lowing year. We obtained data from 1st April 2000 to 31st
March 2013. We excluded patients with a first admission
with ALL in 2000 to exclude prevalent cases.
We used the International Classification of Diseases,
10th revision (ICD-10) code C91.0 to identify cases of
ALL. The main advantage of using HES is complete na-
tional data capture as every adult in England who devel-
oped ALL will almost certainly have been admitted to an
NHS hospital on at least one occasion for confirmation
of the diagnosis and assessment for treatment and sup-
portive care. However, there is significant scope for error
in coding of leukaemia in HES.
We therefore first identified individuals (using the
HES pseudoanonymised identifier) with a C91.0 code in
any diagnosis field and extracted all their admission epi-
sode records. We then carried out a whole series of ex-
ploratory analyses which included examining procedure
codes for chemotherapy, central line insertion, spinal
fluid investigation and bone marrow examination. We
also examined numbers of admissions per patient, cause
of death and diagnoses likely to be miscoded as ALL.
We classified the latter as “ambiguous” diagnoses, which
included other leukaemias (C91.1 – C96.9) and lymph-
omas and myeloma (C81.0 – C90.2).
We arrived at a definition of a case as a patient with
all of the following: a diagnosis of C91.0 as the primary
diagnosis in at least one episode, an admission count >1;
a chemotherapy code recorded in at least one episode;
and a ratio of count of episodes with C91.0 code to
count of episodes containing an ambiguous diagnosis
code >1. Patients admitted for assessment but deemed
too frail to withstand chemotherapy, or who died during
or following their first admission, would have been ex-
cluded by the above definition. We therefore also in-
cluded, as a separate definition, patients with C91.0 as
the cause of death. These patients would also have had a
C91.0 code in any diagnosis field in at least one admis-
sion episode. Records, in at least one episode, of central
line insertion (65.6%), spinal fluid investigation (54.1%)
or bone marrow examination (73.7%) were too incom-
plete to be used in the case definition, given that all pa-
tients undergoing diagnosis and treatment would have
had these procedures carried out. The average number
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of cases identified using the above criteria was 243 per
year and was comparable to the average estimated count
of 240 per year from Office for National Statistics (ONS)
statistics based on cancer registries [18].
Other data
We used the Income Domain of the Index of Multiple
Deprivation (IMD) 2007 as an indicator of socioeco-
nomic deprivation at the small area level [19]. The IMD
is a standard deprivation indicator used by local and na-
tional government and is available at the lower layer
super-output area (LSOA) level. LSOAs are census areas
used in the 2001 and 2011 censuses, with approximately
1500 people per LSOA.
We used the government’s urban-rural classification to
classify LSOAs as either urban or rural [20]. Mid-year
population counts by five-year age band and sex at the
LSOA level were also available from ONS.
Volume and outcome
HES data contain provider unit codes which we used to
estimate the volume of adult patients with ALL treated
at each provider hospital. Provider units have reconfi-
gured over time on several occasions with consequent
changes in codes. We had a consistent set of codes for a
limited time span (1st April 2008 – 31st March 2011)
available from another project, which we used for this
element of the analysis [21]. Estimation of volume was
based on new adult patients with ALL diagnosed during
this three-year time span. Patients could have been ad-
mitted to more than one hospital during this time span
and were included in the volume count of each hospital
they were admitted to. We used the median to split hos-
pitals into high and low volume hospitals.
Statistical analysis
We used Poisson regression to examine incidence, and sur-
vival plots and Cox regression to examine survival. Age
(20–29 years for incidence, 18–29 years for survival, then
10-year bands to 80+ years), gender, rurality, time-period (3
four-year periods) and socioeconomic deprivation (cate-
gorised by tertile) were entered as categorical variables. The
logs of population counts were entered as the offset in the
Poisson regression, which was restricted to 31,672 (97.5%)
of the 32,482 LSOAs in 2001 which remained unchanged
in 2011. Log [−log] plots were consistent with the propor-
tionality assumption for Cox regression. There was no
overdispersion in the Poisson model.
Date of diagnosis and age at diagnosis were based on
the admission date of the first admission with a C91.0
code in any diagnosis field. Survival time was calculated
in years from the date of diagnosis to date of death or
censored at the end of the follow-up period. Analysis of
the effect of volume on survival was examined on the
subset of new patients described above. Results are pre-
sented as rate ratios or hazard ratios, adjusted for all
other variables, with 95% confidence intervals.
Results
Characteristics of patients
There were a total of 2921 adults aged 18 or more years
diagnosed with ALL in the 12-year time span examined,
giving a crude annual incidence of 0.61/100,000 popula-
tion. There were 1870 deaths in 7078 person-years of
follow-up time.
The characteristics of the patients are shown in Table 1.
Almost a quarter of the patients were in the 18–29 year
age group, 42.5% were women and 18.6% lived in rural
areas. There was a median of 23 (Interquartile Range
(IQR) 6–53) admissions per patient within the time period




- 18-29 710 (24.3)
- 30-39 372 (12.7)
- 40-49 401 (13.7)
- 50-59 426 (14.6)
- 60-69 469 (16.1)
- 70-79 361 (12.4)
- 80+ 182 (6.2)
Women 1241 (42.5)
Socioeconomic deprivation (by tertile)
- Least deprived 974 (33.3)
- Intermediate 974 (33.3)
- Most deprived 973 (33.3)
Living in rural areas 544 (18.6)
Time period
- 2001-04 916 (31.4)
- 2005-08 1011 (34.6)




Number of admissions per patient 23 (6–53)
Percentage of admission episodes per patient with
C91.0 in any diagnosis field
95 (81–100)
Percentage of admission episodes per patient with
an ambiguous diagnosis in any diagnosis field
0 (0–5)
Ratio per patient of admission episodes with an
ambiguous diagnosis to episodes with C91.0
0 (0–0.1)
Percentage of admission episodes per patient with
a chemotherapy code
35 (17–56)
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examined. A very high percentage of admission episodes
for each patient had a diagnosis of ALL recorded in one of
the diagnosis fields (median 95% (IQR 81–100%)), with
only a very small percentage of episodes containing an
ambiguous diagnosis code (median 0% (IQR 0–5%).
Incidence rate ratios
The adjusted incidence rate ratios are shown in Table 2.
The incidence rate ratio was 42% (31–53%) higher in
men. Compared with the 20–29 year age group, inci-
dence was lower in patients aged 30–59 years and higher
in patients aged 60+ years. There was no evidence of as-
sociation of incidence with socioeconomic deprivation
or rurality and no evidence of variation over the time
frame examined.
Survival
Figure 1 shows the survival plot for adults diagnosed
with ALL in England from 2001 to 12. The overall five-
year survival for this cohort of 2921 patients was 32%.
When restricted to the 2559 patients who had a record
of chemotherapy, the five-year survival was 36%. The ad-
justed hazard ratios for mortality are shown in Table 3.
These were based on analysis of all 2921 patients.
Hazard ratios increased with increasing age but there
was no evidence of a gender difference in survival. Com-
pared with patients living in the least deprived areas,
survival was poorer in patients living in intermediate
and most deprived areas, with mortality hazard ratios
21% (8–35%) and 16% (3–30%) higher respectively. In
terms of five-year survival, predicted rates for the least,
intermediate and most deprived areas were 36% (33–
38%), 30% (28–33%) and 31% (29–34%) respectively.
There was no association with rurality. Survival im-
proved over the time period examined, and the mortality
hazard ratio was 30% (21–38%) lower in patients pre-
senting in 2009–12 compared with patients presenting
in 2001–04. In terms of five-year survival, predicted
rates for patients presenting in 2001–04, 2005–08 and
2009–12 were 28% (26–31%), 30% (28–33%) and 39%
(36–42%) respectively.
Volume-outcome association
There were 727 new patients admitted between 1st April
2008 and 31st March 2011, the period for which we had
a consistent set of provider unit codes available. Of
these, 465 had all their admissions to the same provider
unit during this time span. The adjusted hazard ratio for
mortality in this subset of 465 patients was 33% (3–73%)
higher in low volume hospitals (Table 3). This analysis
additionally adjusted for chemotherapy treatment as pa-
tients with no record of treatment for chemotherapy had
much poorer survival.
Discussion
Whilst we found no evidence of association between so-
cioeconomic deprivation and incidence of ALL in adults,
survival with higher amongst patients living in affluent
areas. Hospitals treating low volumes of adults with ALL
were associated with poorer survival. Rurality did not
appear to be associated with incidence or survival. Inci-
dence was higher in men but there was no evidence of a
gender difference in survival. Survival improved over
time but was poor amongst older patients.
A review of early studies of childhood ALL found that
higher incidence was associated with higher socioeco-
nomic status [3]. However, a subsequent review found that
the evidence was mixed, with several studies reporting
lower incidence of childhood ALL in more affluent groups
[4]. A more recent study found a non-significant decrease
in incidence with increasing affluence in analyses combin-
ing children and adults [22]. Another study found no evi-
dence of association between incidence and deprivation in
young adults, consistent with our results for all adults [5].
With regard to survival, a national study in the UK on
childhood ALL found that higher levels of socioeco-
nomic deprivation were associated with poorer survival
[9]. The authors argued that the association was not due
Table 2 Adjusted iIncidence rate ratios (95% CI) for ALL in
adults in England, 2001–12
Characteristic Adjusted rate ratio (95% CI)
Age (y)
- 20-29 1
- 30-39 0.65 (0.57–0.74)
- 40-49 0.70 (0.62–0.81)
- 50-59 0.87 (0.76–0.99)
- 60-69 1.19 (1.05–1.35)
- 70-79 1.30 (1.13–1.49)
- 80+ 1.09 (0.92–1.29)
Gender
- Women 1
- Men 1.42 (1.31–1.53)
Socioeconomic deprivation (by tertile)
- Least deprived 1
- Intermediate 0.92 (0.84–1.01)
- Most deprived 0.97 (0.88–1.07)
Urban or rural areas
- Urban 1
- Rural 0.95 (0.86–1.05)
Time period
- 2001-04 1
- 2005-08 1.01 (0.92–1.11)
- 2009-12 0.99 (0.90–1.09)
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to different treatment across social groups as the associ-
ation was also seen in children enrolled in the UKALL
XI trial. Our results indicate that socioeconomic in-
equalities in survival are also a significant cause for con-
cern in adults with ALL and further research is required
to understand and address this issue.
Our finding that mortality was higher for adults
with ALL treated at hospitals treating low volumes of
adult ALL patients is of concern. An early study on
volume and outcome in the treatment of childhood
ALL found that centres treating an average of six or
more patients per year had the best long-term sur-
vival rates [12]. Although two recent childhood ALL
studies found no association between volume and
outcome, they only examined mortality during induc-
tion therapy [13, 14]. A study of in-hospital mortality
in patients undergoing chemotherapy for acute mye-
loid leukaemia, a disease predominantly of adults, was
the first to report that the mortality rate was signifi-
cantly higher in low-volume hospitals [23]. High vol-
ume centres in general are more likely to have
specialised clinical teams and more experienced staff
to manage patients with specific medical conditions,
which could explain better outcomes [24].
Our finding of improved survival over the time
period examined is consistent with studies of adults
with ALL in Germany, the USA and the Netherlands
[15, 16]. We found no gender differences in survival.
Others have reported that whilst survival was worse
in men previously, the gender difference appears to
no longer be apparent [15]. Survival, however, re-
mains poor, especially amongst older adults and those
with relapsed or refractory disease [1, 25].
Our study has a number of potential limitations which
need to be considered. We used HES data which has the
advantage of being a comprehensive national system and
all adults with ALL are likely to have been admitted at
least once to confirm the diagnosis. However, coding and
data entry errors could have led to over or underascertain-
ment of cases. We examined the data in detail in order to
arrive at a set of procedures to keep errors to a minimum.
The average case counts we obtained were comparable to
the ONS estimates from cancer registration data. In
addition, the five-year survival of 36% we observed for pa-
tients receiving chemotherapy is consistent with the five-
year survival of 38% for adults in the UKALL 12 trial [26].
There may have been errors in the mid-year population
estimates we used to calculate incidence rates. We used
an area based measure of socioeconomic deprivation
assigned to individual patients and some patients may
have been misclassified. However, we used a measure
based on small geographical areas which would have mini-
mised this error as levels of socioeconomic deprivation for
populations in smaller geographical units are likely to be
generally more homogenous. The volume indicator was
based on a relatively small number of cases because of the
limited time span for which we had consistent provider
unit codes, and some providers may have been misclassi-
fied by volume. However, misclassification in this context
might have diluted the strength of the association. Poten-
tial errors need to be taken into account in the interpret-
ation of our results.
Conclusions
In terms of future research and policy, further work is
needed to confirm the association between higher
Fig. 1 Survival plot for adults with ALL in England, 2001–12
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socioeconomic deprivation and poorer survival and the ob-
servation that hospitals treating a low volume of patients
were associated with poorer outcome for adults with ALL.
These findings, if confirmed, are likely to have significant
implications for the organisation of services for the treat-
ment of adults with ALL.
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